Literature DB >> 6206358

Thymic stroma in AKR mice: its function and virus production.

E F Hays, S K Swanson, L Hale, N Margaretten.   

Abstract

This study reports experiments with thymic stromal remnants in AKR mice, a strain with a high natural incidence of thymic lymphoma. A method has been developed in which thymic stromal cells which survive a 4-week culture period, 1 week at 24 degrees C and 3 weeks at 37 degrees C are suitable for grafting. Most thymic lymphocytes die under these conditions. Stromal remnants were studied by culturing and grafting under the kidney capsule of 2-month-old syngeneic mice. Their in vitro morphology and virus production, their ability to reconstitute a new thymus from host progenitors and their eventual lymphoma development was evaluated. The stromal remnants were from: 1- and 3-month-old normal mice; 6-10-month-old normal mice; 21-28-day-old animals treated with the lymphomagenic virus, SL3-3, at 3 days of age. Our data show that thymic stromal function as measured by lymphoid reconstitution of thymic stromal grafts of AKR mice is not impaired with age or by the presence of oncogenic virus. Oncogenic viruses are found in the thymic stroma of old mice and in thymic stroma of young virus-treated mice. Oncogenic viruses are not found in thymic stroma of young normal mice. Lymphoma can develop in the grafted stromal remnants expressing lymphomagenic virus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206358     DOI: 10.1016/0145-2126(84)90012-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Macrophages are the first thymic cells to express polytropic retrovirus in AKR mouse leukemogenesis.

Authors:  S Y Kim; L H Evans; F G Malik; R V Rouse
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

2.  Thymic dendritic cells are primary targets for the oncogenic virus SL3-3.

Authors:  C H Uittenbogaart; W Law; P J Leenen; G Bristol; W van Ewijk; E F Hays
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.